A Phase I/II study of crizotinib for recurrent or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma and a phase i study of crizotinib for recurrent or refractory neuroblastoma: Study protocol for a multicenter single-arm open-label trial

Masahiro Sekimizu, Tomoo Osumi, Reiji Fukano, Yuhki Koga, Akiko Kada, Akiko M. Saito, Tetsuya Mori

研究成果: ジャーナルへの寄稿学術誌査読

10 被引用数 (Scopus)

抄録

Crizotinib is an inhibitor of multiple tyrosine kinases, including the anaplastic lymphoma kinase (ALK). Responses to crizotinib have also been reported in patients with ALK-positive anaplastic large-cell lymphoma (ALCL) and solid tumors with ALK-mutation, including neuroblastoma. Optimal treatment for patients with recurrent or refractory ALK-positive ALCL and neuroblastoma has not been established. There is a need to develop new drugs for these patients. The objectives of this trial are to evaluate the tolerability and safety of crizotinib in Japanese patients with recurrent/refractory ALK-positive ALCL or neuroblastoma (phase I) and its efficacy in recurrent/refractory ALK-positive ALCL (phase II).

本文言語英語
ページ(範囲)431-436
ページ数6
ジャーナルActa medica Okayama
72
4
出版ステータス出版済み - 2018

!!!All Science Journal Classification (ASJC) codes

  • 生化学、遺伝学、分子生物学(全般)

フィンガープリント

「A Phase I/II study of crizotinib for recurrent or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma and a phase i study of crizotinib for recurrent or refractory neuroblastoma: Study protocol for a multicenter single-arm open-label trial」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル